How can glycolysis control tumor aggressiveness and response to chemotherapy ?

SEMINAR

Dr. JEAN-EHRLAND RICCI

The increased dependence for glycolysis (Warburg effect) is a common feature of several malignant tumors and is hypothesized to be a key step in tumorigenesis. It has long been considered that the overexpression of glycolytic enzymes is only required to meet the energy demands of cancer cells, and only recently have non-glycolytic roles of these enzymes been identified. During this presentation we will discuss the role of glycolysis in cancer and see how the non-glycolytic function of an enzyme can modulate lymphoma aggressiveness and response to chemotherapy.

Host : Prof. Christian Widmann

_{1: Chiche J, Pommier S, Beneteau M, Mondragón L, Meynet O, Zunino B, Mouchotte A, Verhoeyen E, Guyot M, Pagès G, Mounier N, Imbert V, Colosetti P, Goncalvès D, Marchetti S, Brière J, Carles M, Thieblemont C, Ricci JE. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-κB-dependent induction of HIF-1α. Leukemia. 2014 Nov 14. doi: 10.1038/leu.2014.324. [Epub ahead of print] PubMed PMID: 25394713.}

_{2: Muñoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012 Jan 12;3:e248. doi: 10.1038/cddis.2011.123. Review. PubMed PMID: 22237205; PubMed Central PMCID: PMC3270265.}